Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Recruiting · NCT07471841 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-09-02 | NCT07471841 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Atrium Health Wake Forest Baptist | 13 |
| Rigel Pharmaceuticals | 13 |
| Timothy Pardee | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atrium Health Wake Forest Baptist Medical Center | Winston-Salem | United States | 15 |